Insider · CIK 0001317507
Derek Jason Mullins
Files at MGLD (Marygold Companies, Inc.). First filing -, latest -.
In brief
Derek Jason Mullins files SEC Form 4 as director at MGLD (Marygold Companies, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Derek Jason Mullins has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 7, 2025 | MGLD Marygold Companies, Inc. | AGrant or award Common Stock | +4,854 | $1.03 | $5,000 | 14,779 | Nov 10, 2025 |
| Mar 29, 2023 | MGLD Marygold Companies, Inc. | AGrant or award Common Stock | +2,924 | $1.71 | $5,000 | 2,924 | Dec 12, 2024 |
| Dec 6, 2024 | MGLD Marygold Companies, Inc. | AGrant or award Common Stock | +3,623 | $1.38 | $5,000 | 6,444 | Dec 12, 2024 |
| Dec 9, 2024 | MGLD Marygold Companies, Inc. | AGrant or award Common Stock | +3,378 | $1.48 | $4,999 | 9,925 | Dec 12, 2024 |
Questions about Derek Jason Mullins
Answered from the filings on this page, as of the latest one.
Is Derek Jason Mullins buying or selling?
Derek Jason Mullins has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Derek Jason Mullins's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Derek Jason Mullins has 0.
Where does Derek Jason Mullins file Form 4?
Derek Jason Mullins has filed Form 4 at MGLD (Marygold Companies, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.